Pulse Biosciences (NASDAQ:PLSE) Shares Up 7.5% – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shot up 7.5% during trading on Wednesday . The company traded as high as $25.45 and last traded at $25.7250. 149,008 shares traded hands during trading, a decline of 56% from the average session volume of 334,937 shares. The stock had previously closed at $23.92.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PLSE. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $26.00.

Pulse Biosciences Stock Up 5.6%

The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77. The company’s 50-day moving average price is $14.73 and its 200-day moving average price is $15.59.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently made changes to their positions in PLSE. Portolan Capital Management LLC acquired a new position in shares of Pulse Biosciences during the third quarter valued at approximately $1,809,000. Geode Capital Management LLC increased its position in shares of Pulse Biosciences by 7.2% during the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock worth $7,538,000 after purchasing an additional 33,744 shares in the last quarter. XTX Topco Ltd acquired a new position in Pulse Biosciences in the 2nd quarter valued at $466,000. Brooklyn Investment Group raised its stake in Pulse Biosciences by 5,313.1% in the 3rd quarter. Brooklyn Investment Group now owns 30,259 shares of the company’s stock valued at $536,000 after purchasing an additional 29,700 shares during the last quarter. Finally, Argo Wealth Advisory LLC purchased a new position in Pulse Biosciences in the 4th quarter valued at $387,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.